Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...

Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that ...

Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list.

Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone payments from Sarepta Therapeutics as ...

Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming investor events:. BofA Securities 2025 Health Care Conference– May 13-15, 2025.

It is a rough day to be an investor in Arrowhead Pharmaceuticals (NASDAQ: ARWR). Shares of the clinical-stage biotech are collapsing, falling more than 65% as of 11:36 a.m. EST on Tuesday in ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...

What happened Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (ARWR -11.09%) were up more than 17% Tuesday morning after the company released interim results from a phase 1/2 trial.

If so, you'll want to check out Arrowhead Pharmaceuticals (ARWR -12.23%). SVB Securities, a subsidiary of SVB Financial, recently gave the stock an upgrade to outperform and raised its price target.